Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0
NCT03226431 is a phase 1 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Ascorbic acid in Lung Transplant. The registry lists an enrollment of 6 participants at 1 site in 1 country. The registry lists a start date of 11 Dec 2017 and a primary completion date of 25 Jun 2019.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03226431 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Duke University |
| Enrollment | 6 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Lung Transplant |
| Drugs | Ascorbic acid |
| Start | 11 Dec 2017 |
| Primary completion | 25 Jun 2019 |
| Study completion | 25 Jun 2019 |
| Last update posted | 5 Jul 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Lorenzo Zaffiri, MD
Duke Health
Principal Investigator - Omar Mohamedaly, MD
Duke Health
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Duke University Medical Center
Durham
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03226431
Each answer restates registry values shown on this page.
What is NCT03226431?
NCT03226431 is a phase 1 interventional trial sponsored by Duke University. It studies Ascorbic acid in Lung Transplant.
Who leads NCT03226431?
The registry names Lorenzo Zaffiri, MD (principal investigator, Duke Health) and Omar Mohamedaly, MD (principal investigator, Duke Health) as overall officials.
Where does NCT03226431 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03226431 study?
The registered drug and biological interventions are Ascorbic acid.
When did NCT03226431 end?
The registry lists a primary completion date of 25 Jun 2019 and a study completion date of 25 Jun 2019. The sponsor last updated the record on 5 Jul 2019.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.